{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:31:52Z","timestamp":1790836312126,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","valueinhealthjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jval.2024.05.023","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T17:23:53Z","timestamp":1720113833000},"page":"1358-1366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Uncertainty in Long-Term Relative Effectiveness of Medicines in Health Technology Assessment"],"prefix":"10.1016","volume":"27","author":[{"given":"Jan-Willem","family":"Versteeg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Vreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aukje","family":"Mantel-Teeuwisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Goettsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2024.05.023_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0266462320000215","article-title":"The new definition of health technology assessment: a milestone in international collaboration","volume":"36","author":"O\u2019Rourke","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.jval.2024.05.023_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jval.2019.07.017","article-title":"Differences in health technology assessment recommendations among European jurisdictions: the role of practice variations","volume":"23","author":"Vreman","year":"2020","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2024.05.023_bib3","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cpt.1835","article-title":"Decision making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the United States and Europe","volume":"108","author":"Vreman","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jval.2024.05.023_bib4","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jval.2021.11.1356","article-title":"Reported challenges in health technology assessment of complex health technologies","volume":"25","author":"Hogervorst","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.05.023_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40273-014-0211-5","article-title":"Concepts of \u201cpersonalization\u201d in personalized medicine: implications for economic evaluation","volume":"33","author":"Rogowski","year":"2015","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2024.05.023_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamainternmed.2020.8588","article-title":"Evaluation of the clinical benefit of cancer drugs submitted for reimbursement recommendation decisions in Canada","volume":"181","author":"Meyers","year":"2021","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.jval.2024.05.023_bib7","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.clinthera.2019.07.004","article-title":"Should clinical trials be terminated early?","volume":"41","author":"Streiner","year":"2019","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.jval.2024.05.023_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-015-0349-z","article-title":"Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments","volume":"10","author":"Winstone","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.jval.2024.05.023_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10198-018-1007-x","article-title":"Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare","volume":"20","author":"J\u00f6nsson","year":"2019","journal-title":"Eur J Health Econ"},{"issue":"9","key":"10.1016\/j.jval.2024.05.023_bib10","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s10198-020-01212-w","article-title":"HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies","volume":"21","author":"Coyle","year":"2020","journal-title":"Eur J Health Econ"},{"issue":"S2","key":"10.1016\/j.jval.2024.05.023_bib11","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/1758-5899.12386","article-title":"Managing risk and uncertainty in health technology introduction: the role of managed entry agreements","volume":"8","author":"Kanavos","year":"2017","journal-title":"Glob Policy"},{"issue":"11","key":"10.1016\/j.jval.2024.05.023_bib12","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s40273-020-00943-1","article-title":"Integrative review of managed entry agreements: chances and limitations","volume":"38","author":"Zampirolli Dias","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2024.05.023_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fphar.2018.00280","article-title":"Managed entry agreements for pharmaceuticals in the context of adaptive pathways in Europe","volume":"9","author":"Bouvy","year":"2018","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.jval.2024.05.023_bib14","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jval.2021.11.1373","article-title":"A\u00a0conceptual framework for life-cycle health technology assessment","volume":"25","author":"Kirwin","year":"2022","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.jval.2024.05.023_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.healthpol.2018.09.016","article-title":"Implementing managed entry agreements in practice: the Dutch reality check","volume":"123","author":"Makady","year":"2019","journal-title":"Health Policy (New York)"},{"issue":"1","key":"10.1016\/j.jval.2024.05.023_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0266462309990882","article-title":"Coverage with Evidence Development: applications and issues","volume":"26","author":"Trueman","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.jval.2024.05.023_bib17","doi-asserted-by":"crossref","DOI":"10.1017\/S026646232100177X","article-title":"Addressing uncertainty in relative effectiveness assessments by HTA organizations","volume":"38","author":"Vreman","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.jval.2024.05.023_bib18","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1017\/S0266462321000453","article-title":"Considering and communicating uncertainty in health technology assessment","volume":"37","author":"Trowman","year":"2021","journal-title":"Int J Technol Assess Health Care"},{"issue":"5","key":"10.1016\/j.jval.2024.05.023_bib19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1177\/0272989X221079554","article-title":"Estimating value-based price and quantifying uncertainty around it in health technology assessment: frequentist and bayesian approaches","author":"Hagiwara","year":"2022","journal-title":"Med Decis Making"},{"issue":"3","key":"10.1016\/j.jval.2024.05.023_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.healthpol.2020.12.007","article-title":"Uncertainty tolerance among experts involved in drug reimbursement recommendations: qualitative evidence from HTA committees in Canada and Poland","volume":"125","author":"Wranik","year":"2021","journal-title":"Health Policy (New York)"},{"key":"10.1016\/j.jval.2024.05.023_bib22","author":"Wenzl"},{"issue":"10","key":"10.1016\/j.jval.2024.05.023_bib23","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40273-020-00935-1","article-title":"Surrogate endpoints in health technology assessment: an international review of methodological guidelines","volume":"38","author":"Grigore","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2024.05.023_bib24","article-title":"Raising the bar for using surrogate endpoints in drug regulation and health technology assessment","volume":"374","author":"Dawoud","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jval.2024.05.023_bib25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3390\/ijerph20010340","article-title":"When reality does not meet expectations\u2014experiences and perceived attitudes of Dutch stakeholders regarding payment and reimbursement models for high-priced hospital drugs","volume":"20","author":"Callenbach","year":"2023","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"10.1016\/j.jval.2024.05.023_bib26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jval.2019.12.008","article-title":"Managed entry agreements: policy analysis from the European perspective","volume":"23","author":"Dabbous","year":"2020","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2024.05.023_bib27","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1017\/S0266462321001719","article-title":"Building a model of health technology assessment cooperation: lessons learned from EUnetHTA joint action 3","volume":"38","author":"Garrett","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.jval.2024.05.023_bib28","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1017\/S0266462322000058","article-title":"EUnetHTA relative effectiveness assessments: efforts to increase usability, transparency and inclusiveness","volume":"38","author":"Willemsen","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"issue":"5","key":"10.1016\/j.jval.2024.05.023_bib30","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10198-021-01400-2","article-title":"Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective","volume":"23","author":"Kisser","year":"2022","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2024.05.023_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.hpopen.2021.100032","article-title":"Stakeholder views of managed entry agreements: a literature review of national studies","volume":"2","author":"Thanimalai","year":"2021","journal-title":"Health Policy Open"},{"issue":"1","key":"10.1016\/j.jval.2024.05.023_bib32","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1017\/S0266462323000090","article-title":"Health technology assessment 2025 and beyond: lifecycle approaches to promote engagement and efficiency in health technology assessment","volume":"39","author":"Trowman","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.jval.2024.05.023_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/s41698-022-00316-1","article-title":"A\u00a0perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada","volume":"6","author":"Regier","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"12","key":"10.1016\/j.jval.2024.05.023_bib34","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2217\/cer-2018-0066","article-title":"Real-world evidence for coverage decisions: opportunities and challenges","volume":"7","author":"Hampson","year":"2018","journal-title":"J\u00a0Comp Eff Res"},{"issue":"5","key":"10.1016\/j.jval.2024.05.023_bib35","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524027414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T22:17:08Z","timestamp":1727389028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524027414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1098301524027414"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.05.023","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Uncertainty in Long-Term Relative Effectiveness of Medicines in Health Technology Assessment","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}